ATR Stock Analysis — AptarGroup
Sector: Industrials
AI Verdict
ATR is priced above the sector median despite falling earnings, so you're paying up for a moat that only pays off if growth returns.
Competitive Moat
AptarGroup designs and manufactures specialized dispensing systems for consumer, pharmaceutical, and beauty markets, embedding itself in customer supply chains with custom-engineered solutions. Its defensibility comes from long-term contracts, high switching costs, and regulatory approvals required for many of its pharma products.
Summary
AptarGroup stands out for its custom dispensing systems that lock in major consumer and pharma clients.
Where It Stands
ATR trades at 20.7x next year's earnings, above the industrial sector median of 20x, while analysts expect -9.3% EPS growth and its trailing P/E is 18.8x.
Key Metrics
- Trailing P/E: 18.8x
- Forward P/E: 20.7x
- Earnings Growth: -0.1%
- Revenue Growth: +0.1%
- Dividend Yield: 0.02%
- 52-Week High: $164.28
- 52-Week Low: $103.23
Analyst Consensus
9 Buy · 3 Hold · 0 Sell (12 analysts)
Bull Case
ATR delivered 8.9% revenue growth year-over-year, showing that its core dispensing business is still expanding even as earnings dip.
Bear Case
With forward EPS expected to fall -9.3% and a forward P/E of 20.7x, any P/E compression to the sector median would mean a double-digit hit to the share price.
Catalyst to Watch
Watch for new pharma contract wins or regulatory approvals that could reverse the negative earnings outlook.